A landmark government review in England has concluded that ADHD and autism diagnoses are approaching a critical threshold. Led by Professor Peter Fonagy, the report warns of a potential drift from historical under-diagnosis toward over-diagnosis. The review represents the most comprehensive examination of mental health trends ever conducted in Britain. It has ignited a contentious debate among clinicians, educators, and policymakers alike.
The findings reveal a striking discrepancy between diagnostic rates and estimated prevalence in the population. More than four percent of children aged six to seventeen now hold an autism diagnosis in England. Yet epidemiological studies suggest the true prevalence remains between one and two percent. Similarly, recorded ADHD diagnoses have risen more than sixfold, though underlying rates appear broadly stable.
Professor Fonagy attributes much of this surge to systemic incentives rather than a genuine increase in conditions. The current framework effectively compels families to obtain a formal diagnosis before accessing educational or workplace support. Consequently, diagnosis has become a gatekeeping mechanism, channelling demand through an already overburdened clinical pathway. Over 560,000 individuals were awaiting ADHD assessment at the end of 2025, a figure seventeen times higher than in 2019.
Critics of the review caution that framing the issue as over-diagnosis could inadvertently undermine legitimate need. Researchers have noted that women, older adults, and ethnic minorities remain disproportionately under-diagnosed. The review itself acknowledges that under-diagnosis, misdiagnosis, and over-diagnosis may coexist within the same system simultaneously. Private assessment providers have also drawn scrutiny, with calls for tighter regulation and an advertising ban.
The review's central recommendation is that diagnosis should no longer constitute the sole pathway to assistance. Professor Fonagy has urged that schools and workplaces provide support based on observable need, irrespective of formal clinical labels. Should these reforms be implemented, they could fundamentally reshape how neurodevelopmental conditions are managed across Britain. The final report, with binding recommendations, is still forthcoming.
